Fycompa Approved for Epileptic Seizures
Among people aged 12 and older
MONDAY, Oct. 22 (HealthDay News) -- Fycompa (perampanel) tablets have been approved by the U.S. Food and Drug Administration to treat partial onset seizures in people aged 12 and older who have epilepsy.
Partial onset seizures are the most common seizures in people with epilepsy, a disorder commonly triggered by overactive nerve cells in the brain. Symptoms may include spasms, unusual behavior and loss of consciousness, the FDA said Monday in a news release.
The most common side effects of Fycompa reported during clinical trials included dizziness, sleepiness, irritability, falls, upper respiratory infections and weight gain.
Fycompa's label warns of the possibility of more serious side effects, including aggression, anger, anxiety, paranoia, euphoria and agitation.
The drug is produced by Eisai Inc., of Woodcliff Lake, N.J.
More information
The U.S. National Library of Medicine has more about epilepsy.
Categories
Choose one of our special categories to view or subscribe
- Aging
- Allergies
- Arthritis
- Asthma
- Bone Health
- Cancer
- Cardiovascular Health
- Children's Health
- Colds, Flu, and Infectious Diseases
- Dental Health
- Diabetes
- Diet and Healthy Eating
- Digestive Health
- Drugs and Supplements
- Emotional and Mental Health
- Fitness and Exercise
- Geriatric Care
- Incontinence
- Men's Health
- Menopause
- Neurologic Health
- Pregnancy
- Sexual Health
- Skin Problems
- Sleep Disorders
- Stroke
- Vaccinations
- Weight Management
- Women's Health

